Marchex Q3 Loss Widens on Revenue Dip, Cash Declines

TL;DR

**Marchex is bleeding cash and revenue, making it a risky bet despite cost cuts and a new buyback program.**

AI Summary

Marchex, Inc. reported a net loss of $1.02 million for the three months ended September 30, 2025, an increase from the $0.83 million net loss in the same period of 2024. Revenue decreased by 8.3% to $11.51 million in Q3 2025 from $12.55 million in Q3 2024. For the nine months ended September 30, 2025, the net loss was $2.92 million, a slight improvement from $3.04 million in the prior year, despite a revenue decline to $34.57 million from $36.20 million. Operating expenses decreased to $12.46 million in Q3 2025 from $13.38 million in Q3 2024, primarily due to reduced product development costs, which fell from $3.11 million to $2.37 million. Cash and cash equivalents declined to $10.32 million as of September 30, 2025, from $12.77 million at December 31, 2024. A new share repurchase program for up to 3,000,000 shares of Class B common stock was authorized in May 2025, superseding prior programs. The company continues to operate in a single segment focused on conversational analytics, with 98% of revenue from the United States.

Why It Matters

Marchex's widening net loss and declining revenue in Q3 2025, coupled with a significant drop in cash reserves, signal potential challenges for investors. The company's reliance on a single major customer, accounting for 11% of revenue and 21% of receivables, introduces concentration risk. While operating expenses decreased, the core business revenue decline suggests competitive pressures in the conversational intelligence market, impacting future growth prospects and potentially affecting employee morale and customer retention. The new share repurchase program could offer some support to the stock price, but fundamental performance remains a concern.

Risk Assessment

Risk Level: high — Marchex reported a net loss of $1.02 million in Q3 2025, an increase from $0.83 million in Q3 2024, and cash and cash equivalents decreased by $2.45 million to $10.32 million over the nine months ended September 30, 2025. Revenue declined by 8.3% in Q3 2025, and the company has significant customer concentration with one customer representing 11% of revenue and 21% of accounts receivable.

Analyst Insight

Investors should exercise caution and consider reducing exposure to MCHX given the consistent net losses, declining revenue, and significant cash burn. Monitor future filings closely for any signs of revenue stabilization or improved profitability, as the current trends suggest ongoing operational challenges.

Financial Highlights

debt To Equity

0.29

revenue

$11.51M

operating Margin

-8.17%

total Assets

$41.145M

total Debt

$9.203M

net Income

-$1.02M

eps

N/A

gross Margin

63.0%

cash Position

$10.32M

revenue Growth

-8.3%

Revenue Breakdown

Key Numbers

• $11.51M — Q3 2025 Revenue (down from $12.55M in Q3 2024)
• $1.02M — Q3 2025 Net Loss (increased from $0.83M in Q3 2024)
• $10.32M — Cash and Cash Equivalents (as of September 30, 2025, down from $12.77M at Dec 31, 2024)
• 8.3% — Revenue Decrease (Q3 2025 vs Q3 2024)
• 11% — Customer A Revenue Concentration (for the nine months ended September 30, 2025)
• 21% — Customer A Accounts Receivable Concentration (as of September 30, 2025)
• 3,000,000 — Class B Common Stock Repurchase Authorization (under the 2025 Repurchase Program)
• $2.92M — Nine Months Ended Sep 30, 2025 Net Loss (compared to $3.04M in the prior year)

Key Players & Entities

• Marchex, Inc. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• NASDAQ STOCK MARKET LLC (company) — exchange for Class B Common Stock
• FASB (regulator) — Financial Accounting Standards Board
• Customer A (company) — major customer representing 11% of revenue and 21% of receivables
• Delaware (regulator) — state of incorporation
• Bloomberg (company) — publisher of analysis

FAQ

Risk Factors

• Declining Revenue and Increasing Net Loss [high — financial]: The company reported an 8.3% decrease in revenue for Q3 2025 ($11.51M vs $12.55M in Q3 2024) and an increased net loss of $1.02M vs $0.83M. For the nine months, revenue declined to $34.57M from $36.20M, with a net loss of $2.92M compared to $3.04M.
• Deteriorating Cash Position [medium — financial]: Cash and cash equivalents decreased to $10.32M as of September 30, 2025, from $12.77M at December 31, 2024. This reduction in liquidity could impact the company's ability to fund operations and investments.
• Concentration Risk from Key Customer [medium — operational]: A single customer accounted for 11% of revenue and 21% of accounts receivable as of September 30, 2025. Dependence on this customer poses a significant risk if their business with Marchex declines or ceases.
• Reduced Product Development Spending [low — operational]: Product development costs decreased significantly to $2.37M in Q3 2025 from $3.11M in Q3 2024. While this reduced expenses, it could potentially impact future innovation and competitiveness.
• Share Repurchase Program [low — financial]: A new share repurchase program for up to 3,000,000 shares of Class B common stock was authorized. While intended to return value, it utilizes company cash that could otherwise be used for growth initiatives or debt reduction.

Industry Context

Marchex operates in the conversational analytics sector, a niche within the broader customer engagement and AI technology market. The industry is characterized by rapid technological advancements and increasing demand for data-driven insights into customer interactions. Competitors range from large enterprise software providers to specialized AI firms, all vying to offer solutions that improve customer experience and operational efficiency.

Regulatory Implications

As a technology company handling customer data, Marchex is subject to data privacy regulations such as GDPR and CCPA. Compliance with these evolving regulations is crucial to avoid fines and maintain customer trust. Changes in data handling or privacy laws could necessitate significant adjustments to its services and operations.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $11.51M revenue and $1.02M net loss, with cash and cash equivalents at $10.32M.
• 2025-05-01: Authorization of new share repurchase program — Authorized repurchase of up to 3,000,000 Class B shares, indicating management's strategy to potentially return capital to shareholders.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents stood at $12.77M.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents a negative balance in retained earnings. (Marchex has an accumulated deficit of $329.1M as of September 30, 2025, indicating it has historically incurred more losses than profits.)

Right-of-use lease assets

Assets recognized under accounting standards for leases, representing the lessee's right to use an underlying asset for the lease term. (The company has $0.75M in right-of-use lease assets as of September 30, 2025, reflecting its obligations for leased properties or equipment.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Marchex has $17.56M in goodwill, suggesting past acquisitions where the purchase price exceeded the fair value of the acquired assets.)

Deferred revenue

Revenue that has been received by a company but not yet earned, typically because the goods or services have not yet been delivered or performed. (The company had $0.43M in deferred revenue as of September 30, 2025, representing future obligations to customers.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Marchex Inc. has experienced a notable revenue decline, with Q3 2025 revenue down 8.3% and nine-month revenue down 4.5%. While the net loss for the nine months has slightly improved, the Q3 net loss has widened. Operating expenses have been reduced, primarily through decreased product development costs, which has helped mitigate some of the impact of lower revenue on the bottom line. Cash reserves have also diminished, indicating a tighter financial position.

Key Financial Figures

• $0.01 — hich registered Class B Common Stock, $0.01 par value per share MCHX The NASDAQ

Filing Documents

• mchx-20250930.htm (10-Q) — 2147KB
• mchx-ex10_17.htm (EX-10.17) — 65KB
• mchx-ex31_1.htm (EX-31.1) — 18KB
• mchx-ex31_2.htm (EX-31.2) — 17KB
• mchx-ex32.htm (EX-32) — 26KB
• 0001193125-25-282989.txt ( ) — 8541KB
• mchx-20250930.xsd (EX-101.SCH) — 836KB
• mchx-20250930_htm.xml (XML) — 1874KB

Notes to Consolidated Financial Statements (Unaudited)

Notes to Consolidated Financial Statements (Unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II. OTHER INFORMATION 23 Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 4. Mine Safety Disclosures 36 Item 5. Other Information 36 Item 6. Exhibits 37 Signature 38 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Consolidated Financial Statements

Item 1. Consolidated Financial Statements MARCHEX, INC. AND SUBSIDIARIES Consolida ted Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 10,321 $ 12,767 Accounts receivable, net 7,396 7,072 Prepaid expenses and other current assets 2,686 2,439 Total current assets 20,403 22,278 Property and equipment, net 1,722 1,811 Other assets, net 714 397 Right-of-use lease assets 748 1,156 Goodwill 17,558 17,558 Total assets $ 41,145 $ 43,200 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,640 $ 1,349 Accrued benefits and payroll 1,026 2,133 Other accrued expenses and current liabilities 3,627 4,197 Deferred revenue and deposits 430 1,093 Operating lease liability, current 342 495 Total current liabilities 8,065 9,267 Deferred tax liabilities 678 579 Operating lease liability, non-current 460 721 Total liabilities $ 9,203 $ 10,567 Commitments and contingencies - See Note 10 Stockholders' equity: Common stock, $ 0.01 par value; Authorized 137,500 shares Class A: 12,500 shares authorized; 4,661 shares issued and outstanding at September 30, 2025 and December 31, 2024 $ 49 $ 49 Class B: 125,000 shares authorized; 39,247 shares issued and outstanding at September 30, 2025, including 113 shares of restricted stock; and 39,025 shares issued and outstanding at December 31, 2024, including 365 shares of restricted stock 393 390 Additional paid-in capital 360,596 358,372 Accumulated deficit ( 329,096 ) ( 326,178 ) Total stockholders' equity 31,942 32,633 Total liabilities and stockholders' equity $ 41,145 $ 43,200 See accompanying Notes to the Consolidated Financial Statements. 1 Table of Contents MARCHEX, INC. AND SUBSIDIARIES Consolidated S tatements of Operations